AstraZeneca's Wainua fails primary endpoint in ATTR-CM Phase III trial
The CARDIO-TTRansform Phase III trial for Wainua (eplontersen) did not meet its primary efficacy endpoint.
Therapeutic Area
Therapeutic area intelligence for ATTR-CM with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.